Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ

Journal of Immunotherapy

Volumn 19, Issue 2, 1996, Pages 113-124

  Bausero, Maria A ^a   Panoskaltsis Mortari, Angela ^a   Blazar, Bruce R ^a   Katsanis, Emmanuel ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

GM CSF; IFN ; Immunization; Mice; Neuroblastoma

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IRRADIATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL;

EID: 0029874990     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199603000-00004     Document Type: Article

References (46)

1. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165: 302-19.
2. Katsanis E, Xu Z, Bausero MA, et al. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther 1995;2:39-46.
3. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother 1994;15:81-90.
4. Katsanis E, Bausero MA, Xu H, et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunol Immunother 1994;38:135-41.
5. Katsanis E, Bausero MA, Panoskaltis-Mortari A, et al. Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-γ reduces their capacity to induce systemic immunity. Cancer Gene Ther 1996;3:75-82.
6. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
7. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
8. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:945-60.
9. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by b7-transfected tumors. Cancer Res 1994;54:6477-83.
10. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995;154:5302-12.
11. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
12. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Bio Techniques 1989;7:980-90.
13. Nohava K, Malipiero U, Frei K, Fontana A. Neurons and neuroblastoma as a source of macrophage colony-stimulating factor. Eur J Immunol 1992;22:2539-45.
14. Nitta T, Sato K, Allegretta M, et al. Expression of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor genes in human astrocytoma cell lines and in glioma specimens. Brain Res 1992;571:19-25.
15. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D. Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 1980;152:1036-47.
16. Jaffee EM, Dranoff G, Cohen LK, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993;53:2221-6.
17. Razi-Wolf Z, Freeman GJ, Galvin F, Benacerraf B, Nadler L, Reiser H. Expression and function of the murine B7 antigen the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci USA 1992;89: 4210-4
18. Katsanis E, Blazar BR, Bausero MA, Gunther R, Anderson PM. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. J Pediatr Surg 1994;29:538-42.
19. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of murine T cell surface molecule designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J Immunol 1983;131:2445-53.
20. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell mediated cytolysis in the absence of complement. J Immunol 1980;125:2665-73.
21. Crowley MT, Inaba K, Witmer-Pack MD, Gezelter S, Steinman RM. Use of the fluorescence activated cell sorter to enrich dendritic cells from mouse spleen. J Immunol Methods 1990;133:55-66.
22. Hsu SM. Immunohistochemistry. Methods Enzymol 1990; 184:357-63.
23. Weibel ER. Point counting methods. In: Weibel ER, ed. Stereological methods: practical methods for biological morphometry, vol 1. New York: Academic Press, 1979:101.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc 1972;A135:185-207.
26. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
27. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 1994; 152:2324-32.
28. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
29. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA 1993;90: 3038-42.
30. Frosch S, Bonifas U, Eck HP, et al. The efficient bovine insulin presentation capacity of bone marrow-derived macrophages activated by granulocyte-macrophage colony-stimulating factor correlates with a high level of intracellular reducing thiols. Eur J Immunol 1993;23:1430-4.
31. Fischer HG, Frosch S, Reske K, Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol 1988;141:3882-8.
32. Kato T, Inaba K, Ogawa Y, et al. Granulocyte-macrophage colony-stimulating factor enhances macrophage accessory function in con A-stimulated T-cell proliferation. Cell Immunol 1990;130:490-500.
33. Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139:1113-9.
34. Smith PD, Lamerson CL, Wong HL, Wahl LM, Wahl SM. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol 1990;144:3829-34.
35. Fischer HG, Opel B, Reske K, Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor-cultured bone marrow-derived macrophages reveal accessory cell function and synthesis of MHC class II determinants in the absence of external stimuli. Eur J Immunol 1988;18:1151-8.
36. Steinman RM, Koide S, Witmer M, et al. The sensitization phase of T-cell-mediated immunity. Ann N Y Acad Sci 1988; 546:80-90.
37. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991;137:429-37.
38. Schuurman B, Heuff G, Beelen RH, Meyer S. Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon gamma. Cancer Immunol Immunother 1994; 39:179-84.
39. Reiter Z. Interferon - a major regulator of natural killer cell-mediated cytotoxicity. [Review]. J Interferon Res 1993;13: 247-57.
40. Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P. Reversal of natural killing susceptibility in target cells expressing transfected class HLA gene. Proc Natl Acad Sci USA 1989;86:2361-64.
41. Trinchieri G, Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells: enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978;147:1314-33.
42. Welsh RM, Karre K, Hansson M, Kunkel LA, Kiessling RW. Interferon-mediated protection of normal and tumor target cells against lysis by mouse natural killer cells. J Immunol 1981;126:219-25.
43. Pena J, Alonso C, Solana R, Serrano R, Carracedo J, Ramirez R. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol 1990;20:2445-9.
44. Dennert G, Landon C, Lord EM, Bahler DW, Frelinger JG. Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens. J Immunol 1988;140:2472-5.
45. Sigal RK, Lieberman MD, Reynolds JV, Shou J, Ziegler MM, Daly JM. Low-dose interferon gamma renders neuroblastoma more susceptible to interleukin-2 immunotherapy. J Pediatr Surg 1991;26:389-95.
46. Habu S, Fukui H, Shimamura M, et al. In vivo effects of anti-asialo-GM1: reduction of NK activity and enhancement of transplanted tumor in nude mice. J Immunol 1981;127: 34-8.